In the published article, there was an error in Figure 3E and Figure 6 as published. The H&E image of the brain of OMO-100 in Figure 3E was used incorrectly, and the IHC images in Figure 6 were misused. The corrected Figure 3 and Figure 6 and their captions appear below.
Figure 3
Effect of OMO in Aβ1-42-induced deficient rats. (A) Body weight changes during the treatments time. (B-a) Escape latency in the MWM. (B-b) Swimming distance. (B-c) Swimming time in the platform quadrant during the spatial probe test. (C) Level of cytokines GM-CSF, TNF-γ, 1L-10, IL-12, 1L-17α, 1L-4, TNF-α, and VGEF-α in the serum. (D) Levels of monoamine neurotransmitters (NE, DA, 5-HT, and 5-HIAA) in the brain tissue. (E) Histopathological changes in the intestine, heart, and brain, and the expressions of Aβ1 − 42 and Tau proteins in brain tissues by immunohistochemistry. The graph Control, control group; Model, model group; OMO-50 mg, low-dose group that received D-galactose (100 mg/kg/d) i.p. and gavage at a dosage of 50 mg/[kg·d] in OMO; OMO-100 mg, high-dose group that received D-galactose (100 mg/kg/d) i.p. and gavage at a dosage of 100 mg/[kg·d] in OMO. Values are represented as mean ± SD (n = 6) and expressed as the percentage of the control group, #p < 0.01 vs. control group, *p < 0.05 vs. model group, **p < 0.01 vs. model group.
Figure 6
Immunohistochemistry staining of Foxp3 (A), IL-17 (B), NF-κB p65 (C), and TNF-α (D) in the colons of different experimental groups in high-dose broad spectrum antibiotics and TNBS-induced IBD mice after treatment with OMO.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
fructooligosaccharides, prebiotics, Alzheimer's disease, behavior, microbiota-gut-brain axis
Citation
Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, Shuai O, Zhou G, Xie Y and Wu Q (2025) Corrigendum: Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer's disease in rodent models by targeting the microbiota-gut-brain axis. Front. Aging Neurosci. 17:1593725. doi: 10.3389/fnagi.2025.1593725
Received
14 March 2025
Accepted
28 April 2025
Published
14 May 2025
Volume
17 - 2025
Edited and reviewed by
Pradip Pradip Behare, National Dairy Research Institute (ICAR), India
Updates
Copyright
© 2025 Chen, Yang, Yang, Lai, Yong, Tang, Shuai, Zhou, Xie and Wu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Diling Chen diling1983@163.comYizhen Xie xieyizhen@126.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.